Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT02393703
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients. The results of this study will be the basis for future studies exploring this area.

Key Dates

Start date
Mar 31, 2015
Status verified
Feb 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
181 participants (estimated)

Primary Outcome Measure

successful isolation of exosomes [ Time Frame: 1 year ]

Central Contacts

  • William Jarnagin, MD
    212-639-7601
  • Peter Kingham, MD
    212-639-5260

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
William R Jarnagin, MD
212-639-7601
Peter Kingham, MD
212-639-5260
William R Jarnagin, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Memorial Sloan Kettering Cancer Center· New York, NY

Related Studies